Current Report Filing (8-k)
May 02 2017 - 6:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 1, 2017
BIOSTAGE, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-35853
|
45-5210462
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
84 October Hill Road, Suite 11, Holliston, MA
|
01746
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including
area code:
(774) 233-7300
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 7.01 Regulation FD Disclosure.
On May 1, 2017, Biostage, Inc., or the Company, posted an updated
version of its investor presentation on its website, which the Company may use from time to time. Investors should read the updated
investor presentation in its entirety, including the cautionary statement regarding forward looking statements in the beginning
of the presentation. The forward looking statements in the updated investor presentation involve known and unknown risks, uncertainties
and other factors that may cause the Company’s actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements.
To view the updated investor presentation, please visit the
following link: http://ir.biostage.com/events-and-presentations
The information disclosed under this Item 7.01 is being furnished
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and
shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such filing.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
BIOSTAGE, INC.
|
|
|
(Registrant)
|
|
|
|
May 1, 2017
|
|
/s/ Thomas McNaughton
|
(Date)
|
|
Thomas McNaughton
|
|
|
Chief Financial Officer
|
Biostage (QB) (USOTC:BSTG)
Historical Stock Chart
From May 2024 to Jun 2024
Biostage (QB) (USOTC:BSTG)
Historical Stock Chart
From Jun 2023 to Jun 2024